Middle East & Africa Human Microbiome Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The human microbiome market in the Middle East and Africa is projected to grow significantly, reaching an estimated US$ 48.22 million by 2031, up from US$ 182.83 million in 2023, with a compound annual growth rate (CAGR) of 18.1% from 2023 to 2031.

Executive Summary and Market Analysis

The market is divided into key regions: Saudi Arabia, the UAE, South Africa, and the broader Middle East and Africa. The region is witnessing a rise in chronic diseases, including diabetes, skin disorders, Crohn's disease, and cystic fibrosis. Additionally, the increasing prevalence of unhealthy lifestyles is expected to boost the demand for human microbiome products and services. Research and development initiatives by both governments and private companies are anticipated to further stimulate market growth in the coming years.

Market Segmentation

The human microbiome market in the Middle East and Africa is categorized by type, application, and disease type:

Type: The market is split into products and software/services, with the product segment dominating in 2023. This segment includes probiotics and prebiotics.
Application: The market is segmented into therapeutics, diagnostics, and research, with therapeutics holding the largest market share in 2023.
Disease Type: The market is classified into categories such as obesity, diabetes, autoimmune disorders, cancer, gastrointestinal (GIT) issues, and others, with GIT disorders leading the market in 2023.

Market Outlook

Government initiatives play a crucial role in the growth of the human microbiome market. Substantial funding and grants for microbiome research are provided by governments, which accelerates the development of new treatments, devices, and diagnostics. For example, the National Institutes of Health (NIH) has launched the Human Microbiome Project, allocating US$ 115 million over five years to enhance understanding of human health and improve disease prevention, diagnosis, and treatment.

Regulatory frameworks for microbiome-based products are also evolving, which can reduce the time and costs associated with bringing new treatments to market. Well-defined regulations ensure product safety and efficacy, fostering consumer trust and market acceptance.

The field of microbiome-based therapeutics is rapidly expanding, particularly following the recent approval of Vowst by Seres Therapeutics for treating C. difficile infections, which has heightened interest in microbiome therapies.

Country Insights

The human microbiome market in the Middle East and Africa includes South Africa, Saudi Arabia, the UAE, and the Rest of the region, with South Africa holding the largest market share in 2023. The increase in research studies in South Africa is driving market growth. For instance, a study published in PubMed Central in August 2021 highlighted the relationship between clinical and environmental factors and gut microbiota profiles in young South African children, indicating a protective effect of certain microbiota against atopic dermatitis.

The rising incidence of diabetes is also contributing to market growth in South Africa. Dysbiosis, or an imbalance in gut microbiota, is recognized as a potential risk factor for insulin resistance in Type 2 diabetes patients. According to the IDF Diabetes Atlas, approximately 4 million adults in South Africa had diabetes in 2021, with projections suggesting this number could rise to nearly 7 million by 2045. The development of microbiome therapeutics aimed at treating diabetes is further propelling the human microbiome market in the country.

Company Profiles

Key players in the human microbiome market include MaaT Pharma, Ferring Holdings SA, AOBiome Therapeutics Inc, Finch Therapeutics Group Inc, Seres Therapeutics Inc, Merck & Co Inc, Rebiotix, Inc., Yakult Honsha Co., Ltd., IFF Nutrition & Biosciences, and Synthetic Biologics, Inc. These companies are pursuing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products to consumers.

Product Code: BMIRE00032119

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. Middle East & Africa Human Microbiome Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Significant Investments by Key Market Players
- 4.1.2 Government Initiatives
4.2 Market Restraints
- 4.2.1 Challenges During Production of Microbiome
4.3 Market Opportunities
- 4.3.1 Robust Investment in Research and Development
4.4 Future Trends
- 4.4.1 Emergence of Precision Medicine
4.5 Impact of Drivers and Restraints:

5. Human Microbiome Market - Middle East & Africa Analysis

5.1 Middle East & Africa Human Microbiome Market Revenue (US$ Million), 2021-2031
5.2 Middle East & Africa Human Microbiome Market Forecast Analysis

6. Middle East & Africa Human Microbiome Market Analysis - by Type

6.1 Product
- 6.1.1 Overview
- 6.1.2 Product: Middle East & Africa Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.2 Software and Services
- 6.2.1 Overview
- 6.2.2 Software and Services: Middle East & Africa Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Middle East & Africa Human Microbiome Market Analysis - by Application

7.1 Therapeutics
- 7.1.1 Overview
- 7.1.2 Therapeutics: Middle East & Africa Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Diagnostics
- 7.2.1 Overview
- 7.2.2 Diagnostics: Middle East & Africa Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Research
- 7.3.1 Overview
- 7.3.2 Research: Middle East & Africa Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Middle East & Africa Human Microbiome Market Analysis - by Disease Type

8.1 Obesity
- 8.1.1 Overview
- 8.1.2 Obesity: Middle East & Africa Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Diabetes
- 8.2.1 Overview
- 8.2.2 Diabetes: Middle East & Africa Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Autoimmune Disorder
- 8.3.1 Overview
- 8.3.2 Autoimmune Disorder: Middle East & Africa Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Cancer
- 8.4.1 Overview
- 8.4.2 Cancer: Middle East & Africa Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.5 GIT
- 8.5.1 Overview
- 8.5.2 GIT: Middle East & Africa Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Middle East & Africa Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Middle East & Africa Human Microbiome Market - Country Analysis

9.1 Middle East & Africa
- 9.1.1 Middle East & Africa Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.1 Middle East & Africa Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.2 South Africa: Middle East & Africa Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.1.2.1 South Africa: Middle East & Africa Human Microbiome Market Share - by Type
    - 9.1.1.2.2 South Africa: Middle East & Africa Human Microbiome Market Share - by Product
    - 9.1.1.2.3 South Africa: Middle East & Africa Human Microbiome Market Share - by Application
    - 9.1.1.2.4 South Africa: Middle East & Africa Human Microbiome Market Share - by Disease Type
  - 9.1.1.3 Saudi Arabia: Middle East & Africa Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.1.3.1 Saudi Arabia: Middle East & Africa Human Microbiome Market Share - by Type
    - 9.1.1.3.2 Saudi Arabia: Middle East & Africa Human Microbiome Market Share - by Product
    - 9.1.1.3.3 Saudi Arabia: Middle East & Africa Human Microbiome Market Share - by Application
    - 9.1.1.3.4 Saudi Arabia: Middle East & Africa Human Microbiome Market Share - by Disease Type
  - 9.1.1.4 United Arab Emirates: Middle East & Africa Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.1.4.1 United Arab Emirates: Middle East & Africa Human Microbiome Market Share - by Type
    - 9.1.1.4.2 United Arab Emirates: Middle East & Africa Human Microbiome Market Share - by Product
    - 9.1.1.4.3 United Arab Emirates: Middle East & Africa Human Microbiome Market Share - by Application
    - 9.1.1.4.4 United Arab Emirates: Middle East & Africa Human Microbiome Market Share - by Disease Type
  - 9.1.1.5 Rest of Middle East & Africa: Middle East & Africa Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.1.5.1 Rest of Middle East & Africa: Middle East & Africa Human Microbiome Market Share - by Type
    - 9.1.1.5.2 Rest of Middle East & Africa: Middle East & Africa Human Microbiome Market Share - by Product
    - 9.1.1.5.3 Rest of Middle East & Africa: Middle East & Africa Human Microbiome Market Share - by Application
    - 9.1.1.5.4 Rest of Middle East & Africa: Middle East & Africa Human Microbiome Market Share - by Disease Type

10. Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Human Microbiome Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 MaaT Pharma
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Ferring Holdings SA
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 AOBiome Therapeutics Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Finch Therapeutics Group Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Financial Overview
- 11.4.4 SWOT Analysis
- 11.4.5 Key Developments
11.5 Seres Therapeutics Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Merck & Co Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Yakult Honsha Co., Ltd.
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Rebiotix, Inc.
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 IFF Nutrition & Biosciences
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 Synthetic Biologics, Inc.
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 About Us
12.2 List of Abbreviations